Cargando…

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease

BACKGROUND: Homozygous and compound heterozygous variants in glucocerebrosidase (GBA) can cause Gaucher disease (GD), whereas heterozygous variants increase the risk of developing Parkinson's disease (PD). GD patients display altered peripheral immune proteins. However, it is unknown if these a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galper, Jasmin, Balwani, Manisha, Fahn, Stanley, Waters, Cheryl, Krohn, Lynne, Gan‐Or, Ziv, Dzamko, Nicolas, Alcalay, Roy N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248172/ https://www.ncbi.nlm.nih.gov/pubmed/33570220 http://dx.doi.org/10.1002/mds.28525

Ejemplares similares

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease
por: Alcalay, Roy N, et al.
Publicado: (2016)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity
por: Ysselstein, Daniel, et al.
Publicado: (2021)

Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease
por: Mullin, Stephen, et al.
Publicado: (2020)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Gait asymmetry in glucocerebrosidase mutation carriers with Parkinson’s disease
por: Gera, Anjali, et al.
Publicado: (2020)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
por: Atashrazm, Farzaneh, et al.
Publicado: (2018)

Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease
por: MOZAFARI, Hadi, et al.
Publicado: (2021)

WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease Monocytes
por: Wallings, Rebecca L., et al.
Publicado: (2022)

Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

Parkinsonism Associated with Glucocerebrosidase Mutation
por: Sunwoo, Mun-Kyung, et al.
Publicado: (2011)

Glucocerebrosidase mutations in primary parkinsonism
por: Asselta, Rosanna, et al.
Publicado: (2014)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Identification of novel mutations in glucocerebrosidase (GBA) gene in Indian patients with gaucher disease (GD)
por: Ankleshwaria, Chitra, et al.
Publicado: (2014)

Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity
por: Hughes, Laura P., et al.
Publicado: (2021)

Cytokine activity in Parkinson’s disease
por: Dzamko, Nicolas
Publicado: (2023)

A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers
por: McNeill, Alisdair, et al.
Publicado: (2012)

Analysis of common and rare VPS13C variants in late-onset Parkinson disease
por: Rudakou, Uladzislau, et al.
Publicado: (2020)

Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-glucocerebrosidase
por: Jović, Marko, et al.
Publicado: (2012)

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
por: Gatto, Emilia M., et al.
Publicado: (2019)

Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers
por: Moran, Eileen E., et al.
Publicado: (2021)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish
por: Artola, Marta, et al.
Publicado: (2019)

Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
por: Chauhan, Kanchan, et al.
Publicado: (2022)

Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study
por: David, Fabian J., et al.
Publicado: (2021)

Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson’s Disease
por: Kopytova, Alena E., et al.
Publicado: (2023)

Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
por: Almeida, Maria do Rosário
Publicado: (2012)

Progressive decline of glucocerebrosidase in aging and Parkinson's disease
por: Rocha, Emily M, et al.
Publicado: (2015)

The relationship between glucocerebrosidase mutations and Parkinson disease
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase
por: Goldin, Ehud, et al.
Publicado: (2012)

In silico identification of genetic variants in glucocerebrosidase (GBA) gene involved in Gaucher's disease using multiple software tools
por: Manickam, Madhumathi, et al.
Publicado: (2014)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Gaucher-Associated Parkinsonism
por: Li, Yaqiong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_96salh5bunem0hsptbn1ououoo